Legal & General Group
ORMP icon

Legal & General Group’s Oramed Pharmaceuticals ORMP Stock Holding History

Legal & General Group’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,022
Closed -$14K – 3476
2022
Q2 		$14K Sell
3,022
-15,720
-84% -$84K ﹤0.01% 3323
2022
Q1 		$162K Buy
18,742
+2,306
+14% +$23.6K ﹤0.01% 2740
2021
Q4 		$234K Buy
16,436
+13,255
+417% +$277K ﹤0.01% 2663
2021
Q3 		$70K Buy
3,181
+354
+13% +$6.03K ﹤0.01% 2908
2021
Q2 		$38K Buy
+2,827
New +$32.3K ﹤0.01% 3044

Other funds holding ORMP

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Legal & General Group's ORMP Position: Q3 2022 in Review

Legal & General Group sold out of Oramed Pharmaceuticals (ORMP) in Q3 2022, closing a stake of 3,022 shares — an estimated $14K sold.

Legal & General Group first reported a position in ORMP in Q2 2021 and held it in 5 quarters. The position peaked at $234K in Q4 2021. 71 funds tracked by Wall St. Rank hold ORMP as of Q3 2022.

  • Legal & General Group reported no remaining Oramed Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Legal & General Group sold 3,022 Oramed Pharmaceuticals shares in Q3 2022, an estimated $14K.
  • Legal & General Group first reported a position in Oramed Pharmaceuticals in Q2 2021 and held it in 5 quarters.
  • Legal & General Group's Oramed Pharmaceuticals position peaked at $234K in Q4 2021.
  • 71 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2022.

Based on Legal & General Group's 13F filing for Q3 2022, filed 14 Nov 2022.